José Luis García-Giménez
Center for Biomedical Network Research on Rare Diseases
Department of Physiology Medical School
University of Valencia
INCLIVA Health Research Institute
Bachelor in Chemistry in 2002 and Bachelor in Biochemistry in 2004. After obtaining his Ph.D. at the University of Valencia, he worked in Hake?s laboratory at the Adolf Butenandt Institute, LMU University, Munich (Germany).
Dr. García-Giménez holds a scientific position in the Center for Biomedical Network Research (CIBER-ISCIII) in the thematic area of Rare Diseases and he is a professor of the Master in Physiology and the Master in Biomedical Sciences at the Faculty of Medicine of the University of Valencia. Currently, is also the CEO of EpiDisease S.L. , a Biotech Company focused on Epigenetic Biomarkers.
He has co-authored 34 manuscripts and six book chapters. Author of 2 patents in epigenetics ES2396387 and EP 15382319.0 (Epidis-AIS biomarkers).
Over 12 years of continuous research in 20 funded project (as IP or collaborator). Member of the European Innovation Partnership EIP Health for Aging A3. Action Group (commitment Epifrailty: Epigenetic biomarkers related with aging and Health).
Member of the International Rare Diseases Research Consortium (IRDiRC). Translational Research Experimental Medicine, and Therapeutics on Charcot-Marie-Tooth Disease (TREAT-CMT). Editor for the 2015 Translational Epigenetic Series Volume ?Epigenetic Biomarkers and Diagnostics?. 6 National and international awards. National award for Young Entrepreneurs in Social-health category by Epidisease project (2013).
Chromatin remodeling by new post-translational modifications in histones
Epigenetic biomarkers and diagnostics
Sepsis and septic shock